Summary
GlaxoSmithKline (GSK) gained approval for Cervarix in Japan, which becomes the first cervical cancer vaccine to be approved by the Japanese Ministry of Health, Labour and Welfare (MHLW). This approval marks a significant milestone for GSK, as Cervarix will be the first to be launched by the company's Japanese business.
Analysis
Great news, and great advancement!
We know of the current HPV vaccine available in the US and others currently; with this being approved/available in Japan, our fight against cervical cancer "goes global"
As we know there are >20 HPV strains that can and do infect. However, the 11, 16, 18 are the most commonly associated with cervical cancer / genital warts....thus these will be the most targeted strains for vaccines.
If you read more on the subject you will find that men/boys are recommended to get the vaccine as well now...for prevention of genital warts, and to help stop the spread of the cervical CA strains.
This author consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
